clinical trial · NCT04973111
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
Carmot Therapeutics, Inc.·phase1·completed·n = 32
DiabetesCT-868 as SC InjectionPlacebo as SC InjectionActive Comparator as SC Injection
brief summary
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
started
Jul 16, 2021
primary completion
Apr 22, 2022
completion
Apr 22, 2022
last updated
Mar 28, 2025
official title
A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess Pharmacokinetic and Pharmacodynamic Effects of CT-868 on the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol